GlassScriptPhysician profile
Syed Z Mohsin
NPI 1568474674
$4,632.25
in general payments reported to CMS, 2019-2025
52 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $167 · 2021: $487 · 2022: $568 · 2023: $1,022 · 2024: $913 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $617.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $510.72 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $485.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $299.22 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $278.23 | 2019-2025 | |
| Pfizer INC. | $217.64 | 2022-2025 | |
| Amgen INC. | $202.81 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $187.68 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.80 | 2019-2023 | Jardiance |
| Abbvie INC. | $151.76 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $134.02 | 2019-2021 | |
| Intuity Medical INC | $112.42 | 2022 | |
| Neurocrine Biosciences, INC. | $97.23 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.81 | 2023-2024 | |
| Amarin Pharma, INC. | $92.37 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Mohsin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.